resistance in cirrhotic patients with ascites. Hepatology
1998;28:39–44
40. Tristani FE, Cohn JN. Systemic and renal hemodynamics in
oliguric hepatic failure: effect of volume expansion. J Clin
Invest 1967;46:1894–1906
41. Lebrec D, Kotelanski B, Cohn JN. Splanchnic hemodynamic
factors in cirrhosis with refractory ascites. J Lab Clin Med
1979;93:301–309
42. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic,
renal, and hepatic hemodynamic derangement in cirrhotic
patients with spontaneous bacterial peritonitis. Hepatology
2003;38:1210–1218
43. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al.
Circulatory function and hepatorenal syndrome in cirrhosis.
Hepatology 2005;42:439–447
44. Schroeder ET, Eich RH, Smulyan H, Gould AB, Gabuzda
GJ. Plasma renin level in hepatic cirrhosis: relation to
functional renal failure. Am J Med 1970;49:186–191
45. Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role
of the sympathetic nervous system. Semin Liver Dis
1994;14:35–43
46. Arroyo V, Planas R, Gaya J, et al. Sympathetic nervous
activity, renin-angiotensin system and renal excretion of
prostaglandin-e2 in cirrhosis: relationship to functional renal
failure and sodium and water excretion. Eur J Clin Invest
1983;13:271–278
47. Rimola A, Gine`s P, Arroyo V, et al. Urinary excretion of
6-keto-prostaglandin F1 alpha, thromboxane B2 and
prostaglandin E2 in cirrhosis with ascites: relationship to
functional renal failure (hepatorenal syndrome). J Hepatol
1986;3:111–117
48. Moore KP. Arachidonic acid metabolites and the kidney in
cirrhosis. In: Arroyo V, Gine`s P, Rode´s J, Schrier RW, eds.
Ascites and Renal Dysfunction in Liver Disease: Pathogenesis,
Diagnosis, and Treatment. Malden: Blackwell Science;
1999:249–272
49. Angeli P, Albino G, Carraro P, et al. Cirrhosis and muscle
cramps: evidence of a causal relationship. Hepatology 1996;23:
264–273
50. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the
heart of the matter. Hepatology 1996;24:451–459
51. Braverman AC, Steiner MA, Picus D, White H. High-
output congestive heart failure following transjugular intra-
hepatic portal-systemic shunting. Chest 1995;107:1467–1469
52. Gine`s P, Uriz J, Calahorra B, et al. Transjugular intrahepatic
portosystemic shunting versus paracentesis plus albumin for
refractory ascites in cirrhosis. Gastroenterology 2002;123:
1839–1847
53. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver
transplantation. Liver Transpl 2000;6:S44–S52
54. Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac
morbidity and mortality related to orthotopic liver trans-
plantation. Liver Transpl 2004;10:1441–1453
55. Lee SS. Cardiac dysfunction in spontaneous bacterial
peritonitis: a manifestation of cirrhotic cardiomyopathy?
Hepatology 2003;38:1089–1091
56. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous
albumin on renal impairment and mortality in patients with
cirrhosis and spontaneous bacterial peritonitis. N Engl J Med
1999;341:403–409
57. Wiest R, Groszmann RJ. Nitric oxide and portal hyper-
tension: its role in the regulation of intrahepatic and
splanchnic vascular resistance. Semin Liver Dis 1999;19:
411–426
58. Tsai MH, Peng YS, Chen YC, et al. Adrenal insufficiency in
patients with cirrhosis, severe sepsis and septic shock.
Hepatology 2006;43:673–681
59. Fernandez J, Escorsell A, Zabalza M, et al. Adrenal
insufficiency in patients with cirrhosis and septic shock:
effect of treatment with hydrocortisone on survival. Hepatol-
ogy 2006;44:1288–1295
60. Gonwa TA, Morris CA, Goldstein RM, Husberg BS,
Klintmalm GB. Long-term survival and renal function
following liver transplantation in patients with and without
hepatorenal syndrome: experience in 300 patients. Trans-
plantation 1991;51:428–430
61. Gonwa TA, Klintmalm GB, Levy M, et al. Impact of
pretransplant renal function on survival after liver trans-
plantation. Transplantation 1995;59:361–365
62. Seu P, Wilkinson AH, Shaked A, Busuttil RW. The
hepatorenal syndrome in liver transplant recipients. Am Surg
1991;57:806–809
63. Rimola A, Gavaler JS, Schade RR, el-Lankany S, Starzl TE,
Van Thiel DH. Effects of renal impairment on liver
transplantation. Gastroenterology 1987;93:148–156
64. Guevara M, Gine`s P, Fernandez-Esparrach G, et al.
Reversibility of hepatorenal syndrome by prolonged admin-
istration of ornipressin and plasma volume expansion.
Hepatology 1998;27:35–41
65. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and
retreatment of hepatorenal syndrome type 1 with ornipressin
and dopamine. Hepatology 1999;30:870–875
66. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1
hepatorenal syndrome with the administration of midodrine
and octreotide. Hepatology 1999;29:1690–1697
67. Uriz J, Gine`s P, Cardenas A, et al. Terlipressin plus albumin
infusion: an effective and safe therapy of hepatorenal
syndrome. J Hepatol 2000;33:43–48
68. Mulkay JP, Louis H, Donckier V, et al. Long-term
terlipressin administration improves renal function in cirrhotic
patients with type 1 hepatorenal syndrome: a pilot study. Acta
Gastroenterol Belg 2001;64:15–19
69. Colle I, Durand F, Pessione F, et al. Clinical course,
predictive factors and prognosis in patients with cirrhosis and
type 1 hepatorenal syndrome treated with terlipressin: a
retrospective analysis. J Gastroenterol Hepatol 2002;17:882–
888
70. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin
(Glypressin (R)) on hepatorenal syndrome in cirrhotic
94
SEMINARS IN LIVER DISEASE/VOLUME 28, NUMBER 1
2008
patients: results of a multicentre pilot study. Eur J Gastro-
enterol Hepatol 2002;14:153–158
71. Ortega R, Gine`s P, Uriz J, et al. Terlipressin therapy with
and without albumin for patients with hepatorenal syndrome:
results of a prospective, nonrandomized study. Hepatology
2002;36:941–948
72. Duvoux C, Zanditenas D, Hezode C, et al. Effects of
noradrenalin and albumin in patients with type I hepatorenal
syndrome: a pilot study. Hepatology 2002;36:374–380
73. Solanki P, Chawla A, Garg R, et al. Beneficial effects of
terlipressin in hepatorenal syndrome: a prospective, random-
ized placebo-controlled clinical trial. J Gastroenterol Hepatol
2003;18:152–156
74. Wong F, Pantea L, Sniderman K. Midodrine, octreotide,
albumin, and TIPS in selected patients with cirrhosis and
type 1 hepatorenal syndrome. Hepatology 2004;40:55–64
75. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al.
Noradrenalin vs terlipressin in patients with hepatorenal
syndrome: a prospective, randomized, unblinded, pilot study.
J Hepatol 2007;47:499–505
76. Linas SL, Schaefer JW, Moore EE, Good JT, Giansiracusa
R. Peritoneovenous shunt in the management of the
hepatorenal syndrome. Kidney Int 1986;30:736–740
77. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M,
Tran A. Octreotide in hepatorenal syndrome: a randomized,
double-blind, placebo-controlled, crossover study. Hepatol-
ogy 2003;38:238–243
78. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients
with cirrhosis and type-1 hepatorenal syndrome: a retrospective
multicenter study. Gastroenterology 2002;122:923–930
79. Fernandez J, Navasa M, Garcia-Pagan JC, et al. Effect of
intravenous albumin on systemic and hepatic hemodynamics
and vasoactive neurohormonal systems in patients with
cirrhosis and spontaneous bacterial peritonitis. J Hepatol
2004;41:384–390
80. Brensing KA, Textor J, Perz J, et al. Long-term outcome
after transjugular intrahepatic portosystemic stent-shunt in
non-transplant cirrhotics with hepatorenal syndrome: a phase
II study. Gut 2000;47:288–295
81. Guevara M, Gine`s P, Bandi JC, et al. Transjugular
intrahepatic portosystemic shunt in hepatorenal syndrome:
effects on renal function and vasoactive systems. Hepatology
1998;28:416–422
82. Mitzner SR, Stange J, Klammt S, et al. Improvement of
hepatorenal syndrome with extracorporeal albumin dialysis
MARS: results of a prospective, randomized, controlled
clinical trial. Liver Transpl 2000;6:277–286
83. Catalina MV, Barrio J, Anaya F, et al. Hepatic and systemic
haemodynamic changes after MARS in patients with acute
on chronic liver failure. Liver Int 2003;23:39–43
84. Jalan R, Sen S, Steiner C, et al. Extracorporeal liver support
with molecular adsorbents recirculating system in patients
with severe acute alcoholic hepatitis. J Hepatol 2003;38:24–
31
85. Stange I, Hassanein TI, Mehta R, et al. Short-term survival
of patients with severe intractable hepatic encephalopathy:
the role of albumin dialysis. Hepatology 2005;42:286A
86. Lebrec D, Giuily N, Hadengue A, et al. Transjugular
intrahepatic portosystemic shunts—comparison with para-
centesis in patients with cirrhosis and refractory ascites: a
randomized trial. J Hepatol 1996;25:135–144
87. Rossle M, Ochs A, Gulberg V, et al. A comparison of
paracentesis and transjugular intrahepatic portosystemic
shunting in patients with ascites. N Engl J Med 2000;342:
1701–1707
88. Sanyal AJ, Genning C, Reddy KR, et al. The North
American Study for the Treatment of Refractory Ascites.
Gastroenterology 2003;124:634–641
89. Salerno F, Merli M, Riggio O, et al. Randomized controlled
study of TIPS versus paracentesis plus albumin in cirrhosis
with severe ascites. Hepatology 2004;40:629–635
90. Alessandria C, Venon WD, Marzano A, et al. Renal failure
in cirrhotic patients: role of terlipressin in clinical approach to
hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol
2002;14:1363–1368
91. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis
of spontaneous bacterial peritonitis delays hepatorenal
syndrome and improves survival in cirrhosis. Gastroenterol-
ogy 2007;133:818–824
92. Albillos A, de la Hera A, Gonzalez M, et al. Increased
lipopolysaccharide binding protein in cirrhotic patients with
marked immune and hemodynamic derangement. Hepatol-
ogy 2003;37:208–217
93. Frances R, Benlloch S, Zapater P, et al. A sequential study of
serum bacterial DNA in patients with advanced cirrhosis and
ascites. Hepatology 2004;39:484–491
94. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-
Dusting J. The effect of selective intestinal decontamination
on the hyperdynamic circulatory state in cirrhosis: a
randomized trial. Ann Intern Med 2003;139:186–193
95. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline
improves short-term survival in severe acute alcoholic
hepatitis: a double-blind, placebo-controlled trial. Gastro-
enterology 2000;119:1637–1648
PATHOGENESIS AND TREATMENT OF HEPATORENAL SYNDROME/ARROYO ET AL
95